Skip to main content

Table 2 Frequency and incidence of events in the study population (n = 5180)

From: Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database

  

Risk at 5 years

   

Outcomes

N

(%)

CI95%

HR

CI95%

p valuea

Gastrointestinal haemorrhage

 Cilostazol

35

1.2

0.8–1.6

1.10

0.7–1.8

0.711

 Pentoxifylline

31

1.1

0.7–1.4

   

Cerebral haemorrhage

 Cilostazol

23

0.8

0.5–1.1

0.79

0.5–1.4

0.392

 Pentoxifylline

30

1.0

0.7–1.4

   

Other haemorrhages

 Cilostazol

92

3.2

2.5–3.8

0.83

0.6–1.2

0.267

 Pentoxifylline

115

4.0

3.2–4.7

   

Any haemorrhage

 Cilostazol

115

4.0

3.2–4.7

0.82

0.6–1.1

0.119

 Pentoxifylline

143

4.9

4.1–5.7

   

CAD

 Cilostazol

287

9.9

8.8–11.0

0.94

0.8–1.1

0.433

 Pentoxifylline

305

10.5

9.4–11.6

   

Stroke

 Cilostazol

161

5.5

4.7–6.4

0.94

0.8–1.2

0.564

 Pentoxifylline

171

5.9

5.0–6.7

   

AF

 Cilostazol

194

6.7

5.8–7.6

1.02

0.8–1.2

0.857

 Pentoxifylline

190

6.5

5.6–7.4

   

Other arrhythmias

 Cilostazol

89

3.1

2.4–3.7

1.14

0.8–1.5

0.392

 Pentoxifylline

78

2.7

2.1–3.3

   
  1. CI 95% Confidence Interval with 95%, HR hazard ratio, CAD coronary artery disease, AF atrial fibrillation
  2. ap-value computed using univariate Cox regression with robust standard errors by clusters (pairs)
  3. Significant p-values are in boldface